Literature DB >> 1548508

Anti-GM1 antibodies in patients with Guillain-Barré syndrome.

L H van den Berg1, J Marrink, A E de Jager, H J de Jong, G W van Imhoff, N Latov, S A Sadiq.   

Abstract

Anti-GM1 antibodies were measured in 22 patients with the Guillain-Barré syndrome (GBS) and compared with anti-GM1 antibody activity in patients with other neurological or immunological diseases and in normal subjects. Four out of 22 patients with GBS had raised IgM, IgG, or IgA anti-GM1 antibody activities. All four patients were tetraparetic with only minimal or no sensory deficit. Three of the patients had highly raised antibody activity and showed severe residual deficits, while of the remaining patients with GBS, only one remained severely affected. One patient had anti-GM1 antibodies specific for GM1, whereas the other three patients showed antibody activity with asialo-GM1 or GD1b. The presence of anti-GM1 antibodies may define a subgroup of patients with GBS who have a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548508      PMCID: PMC488923          DOI: 10.1136/jnnp.55.1.8

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block.

Authors:  M Santoro; F P Thomas; M E Fink; D J Lange; A Uncini; N H Wadia; N Latov; A P Hays
Journal:  Ann Neurol       Date:  1990-09       Impact factor: 10.422

Review 2.  Antibody detection in Guillain-Barré syndrome.

Authors:  L Svennerholm; P Fredman
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

3.  Rapid calculation of radioimmunoassay results.

Authors:  D Rodbard; W Bridson; P L Rayford
Journal:  J Lab Clin Med       Date:  1969-11

4.  Criteria for diagnosis of Guillain-Barré syndrome.

Authors: 
Journal:  Ann Neurol       Date:  1978-06       Impact factor: 10.422

5.  Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis.

Authors:  N Yuki; H Yoshino; S Sato; T Miyatake
Journal:  Neurology       Date:  1990-12       Impact factor: 9.910

6.  Anti-peripheral nerve myelin antibodies in Guillain-Barre syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssman antigen.

Authors:  C L Koski; D K Chou; F B Jungalwala
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

Authors:  A Pestronk; D R Cornblath; A A Ilyas; H Baba; R H Quarles; J W Griffin; K Alderson; R N Adams
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

8.  The spectrum of neurologic disease associated with anti-GM1 antibodies.

Authors:  S A Sadiq; F P Thomas; K Kilidireas; S Protopsaltis; A P Hays; K W Lee; S N Romas; N Kumar; L van den Berg; M Santoro
Journal:  Neurology       Date:  1990-07       Impact factor: 9.910

9.  Lower motor neuron disease in a patient with autoantibodies against Gal(beta 1-3)GalNAc in gangliosides GM1 and GD1b: improvement following immunotherapy.

Authors:  M E Shy; T Heiman-Patterson; G J Parry; A Tahmoush; V A Evans; P K Schick
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

10.  Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease.

Authors:  N Latov; A P Hays; P D Donofrio; J Liao; H Ito; S McGinnis; M Konstadoulakis; L Freddo; M E Shy; K Manoussos
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

View more
  14 in total

1.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Antiglycolipid antibodies in peripheral neuropathy: fact or fiction?

Authors:  H J Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

4.  Axon loss is an important determinant of weakness in multifocal motor neuropathy.

Authors:  J T H Van Asseldonk; L H Van den Berg; S Kalmijn; R M Van den Berg-Vos; C H Polman; J H J Wokke; H Franssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

5.  Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni.

Authors:  F J Vriesendorp; W J Triggs; R F Mayer; C L Koski
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

6.  Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients.

Authors:  N C Notermans; J H Wokke; H Franssen; Y van der Graaf; M Vermeulen; L H van den Berg; P R Bär; F G Jennekens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

7.  Anti-sulphatide antibodies in peripheral neuropathy.

Authors:  L H van den Berg; C L Lankamp; A E de Jager; N C Notermans; P Sodaar; J Marrink; H J de Jong; P R Bär; J H Wokke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

8.  Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.

Authors:  Amjad A Ilyas; Zi-Wei Chen
Journal:  J Neuroimmunol       Date:  2007-06-07       Impact factor: 3.478

9.  Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy?

Authors:  M Weller; A Stevens; N Sommer; H Wiethölter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

Review 10.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.